About Reapplix
Reapplix is a company based in Rudersdal (Denmark) founded in 2008 by Rasmus Lundquist and Niels Holm.. Reapplix has raised $52.36 million across 9 funding rounds from investors including Accelerace, Novo Holdings and Danmarks Eksport- og Investeringsfond. The company has 10 employees as of February 29, 2024. Reapplix offers products and services including 3C Patch System. Reapplix operates in a competitive market with competitors including Organogenesis, Siren, Sofregen, BioTissue and Encellin, among others.
- Headquarter Rudersdal, Denmark
- Employees 10 as on 29 Feb, 2024
- Founders Rasmus Lundquist, Niels Holm
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Reapplix A/S
-
Annual Revenue
$255.86 K (USD)120as on Dec 31, 2021
-
Net Profit
$-4.99 M (USD)11as on Dec 31, 2021
-
EBITDA
$-5.27 M (USD)11as on Dec 31, 2021
-
Total Equity Funding
$52.36 M (USD)
in 9 rounds
-
Latest Funding Round
$22.73 M (USD), Series B
Jul 07, 2020
-
Investors
Accelerace
& 8 more
-
Employee Count
10
as on Feb 29, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Reapplix
Reapplix offers a comprehensive portfolio of products and services, including 3C Patch System. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Creates patches from patient blood to accelerate diabetic foot ulcer healing.
Unlock access to complete
Funding Insights of Reapplix
Reapplix has successfully raised a total of $52.36M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $22.73 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series B — $22.7M
-
First Round
First Round
(19 Feb 2008)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2020 | Amount | Series B - Reapplix | Valuation |
investors |
|
| Sep, 2019 | Amount | Series A - Reapplix | Valuation | Novo Holdings , Vaekstfonden |
|
| Mar, 2018 | Amount | Series A - Reapplix | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Reapplix
Reapplix has secured backing from 9 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Accelerace, Novo Holdings and Danmarks Eksport- og Investeringsfond. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location | |
|
Provision of financing, loans, equity, and insurance for Danish export and investment activities.
|
Founded Year | Domain | Location | |
|
Venture capital firm backing Nordic tech startups from seed to Series A with investments in Consumer, Deep Tech, and related sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Reapplix
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Reapplix
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Reapplix Comparisons
Competitors of Reapplix
Reapplix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Organogenesis, Siren, Sofregen, BioTissue and Encellin, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Regenerative therapies for wound care are developed and commercialized.
|
|
| domain | founded_year | HQ Location |
Innovative foot care solutions are provided by Siren.
|
|
| domain | founded_year | HQ Location |
Silk-derived biomaterials are developed for soft tissue repair in surgery.
|
|
| domain | founded_year | HQ Location |
Regenerative biologic therapies for eye care are developed and provided.
|
|
| domain | founded_year | HQ Location |
Developer of regenerative materials
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Reapplix
Frequently Asked Questions about Reapplix
When was Reapplix founded?
Reapplix was founded in 2008.
Where is Reapplix located?
Reapplix is headquartered in Rudersdal, Denmark.
Who is the current CEO of Reapplix?
Kira Rupprecht is the current CEO of Reapplix.
Is Reapplix a funded company?
Reapplix is a funded company, having raised a total of $52.36M across 9 funding rounds to date. The company's 1st funding round was a Series A of $9.48M, raised on Feb 19, 2008.
How many employees does Reapplix have?
As of Feb 29, 2024, the latest employee count at Reapplix is 10.
What is the annual revenue of Reapplix?
Annual revenue of Reapplix is $255.86K as on Dec 31, 2021.
What does Reapplix do?
Developer of patch system for wound healing. The company has developed a 3C Patch System that is used to separate, coagulate and pack it into a solid patch consisting of proteins, active cells, and growth factors. The solid patch is applied to the wounds where the patients own growth factors and stem cells are used to heal the wound and diabetic foot ulcers.
Who are the top competitors of Reapplix?
Reapplix's top competitors include Organogenesis, Siren and GeniPhys.
What products or services does Reapplix offer?
Reapplix offers 3C Patch System.
Who are Reapplix's investors?
Reapplix has 9 investors. Key investors include Accelerace, Novo Holdings, Danmarks Eksport- og Investeringsfond, SEED Capital, and North-East.
What is Reapplix's valuation?
The valuation of Reapplix is $41.5M as of Jul 2020.